Commence Phase 3 study for VERU-111 for COVID-19
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 10 Feb 2021
- Due
- 30 Apr 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We plan to commence the VERU-111 for COVID-19 Phase 3 study in April 2021.”
What we found
Evidence strength A What the grades mean
The company planned to commence the Phase 3 study in April 2021, but later reported that it expected to enroll the first patient in May 2021.
-
A Veru Inc. 10-Q filed 2021-05-12
“The Company expects to enroll its first patient in its sabizabulin for COVID-19 Phase 3 pivotal study in May 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Commence
- Deliverable
- VERU-111 for COVID-19 Phase 3 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Veru Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VERU-023434 · Corrections policy